Aberdeen Group plc Grows Holdings in Caribou Biosciences, Inc. $CRBU

Aberdeen Group plc raised its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 54.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,388,905 shares of the company’s stock after purchasing an additional 491,326 shares during the quarter. Aberdeen Group plc owned 1.49% of Caribou Biosciences worth $3,236,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CRBU. Liberty Wealth Management LLC bought a new stake in Caribou Biosciences during the 3rd quarter valued at about $45,000. Hudson Bay Capital Management LP purchased a new position in shares of Caribou Biosciences during the second quarter worth approximately $30,000. Tower Research Capital LLC TRC raised its stake in shares of Caribou Biosciences by 577.9% during the second quarter. Tower Research Capital LLC TRC now owns 74,053 shares of the company’s stock valued at $93,000 after acquiring an additional 63,129 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Caribou Biosciences by 36.9% during the second quarter. Bridgeway Capital Management LLC now owns 148,500 shares of the company’s stock valued at $187,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Caribou Biosciences in the second quarter valued at approximately $196,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Stock Performance

CRBU stock opened at $1.80 on Friday. Caribou Biosciences, Inc. has a one year low of $0.66 and a one year high of $3.54. The firm has a market cap of $168.25 million, a price-to-earnings ratio of -1.06 and a beta of 2.61. The firm has a 50-day simple moving average of $1.60 and a two-hundred day simple moving average of $1.90.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CRBU. HC Wainwright lifted their target price on Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Truist Financial set a $7.00 price objective on Caribou Biosciences in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, January 21st. Finally, Citigroup boosted their price target on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.00.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.